Polyendocrine metabolic ovarian syndrome the new name for pcod , make a ppt of 30 slides from standard journals and articles and books ( lancet )
"polycystic ovary syndrome" AND "polyendocrine metabolic syndrome"
polyendocrine metabolic ovarian syndrome PCOS new name 2024 2025 Lancet
polyendocrine metabolic ovarian syndrome PMOS new name PCOS features diagnosis treatment
polycystic ovary syndrome ultrasound follicles hormonal
PMOS Polyendocrine Metabolic Ovarian Syndrome
Presentation · PPTX
What's Inside (30 Slides)
| # | Slide Title |
|---|---|
| 1 | Title Slide — PMOS, The New Name for PCOS |
| 2 | The Historic Renaming — Lancet, May 12, 2026 |
| 3 | Why PCOS Had to Change — misnomer, delayed diagnosis, stigma |
| 4 | The Global Consensus Process — 6-step infographic |
| 5 | Definition of PMOS — prevalence, scope |
| 6 | Pathophysiology — 6-system overview cards |
| 7 | The 'Polyendocrine' Dimension — all 5 endocrine axes |
| 8 | Epidemiology — stat cards (1 in 8, >170 million, ~70% undiagnosed) |
| 9 | Diagnostic Criteria — Updated Rotterdam 2023 (3 pillars) |
| 10 | Exclusion Criteria — differential diagnoses |
| 11 | Clinical Phenotypes A–D — severity stratification |
| 12 | Clinical Features — 4-column table (reproductive, metabolic, dermatological, psychological) |
| 13 | Imaging — PCOM ultrasound (string of pearls) + criteria |
| 14 | Hormonal & Lab Investigations |
| 15 | Metabolic & Cardiometabolic Complications |
| 16 | Reproductive Health Implications |
| 17 | Psychological Health & QoL |
| 18 | PMOS in Adolescents |
| 19 | PMOS & Pregnancy / Fertility Management |
| 20 | Lifestyle Management — first-line treatment |
| 21 | Pharmacological Management — OCP, metformin, anti-androgens, letrozole |
| 22 | Hyperandrogenism / Dermatological Management |
| 23 | Screening & Monitoring Protocol |
| 24 | Imaging — Bilateral Ovarian Assessment (ultrasound image) |
| 25 | PMOS vs PCOS Framework — comparison table |
| 26 | PMOS in Special Populations |
| 27 | Global Implementation Strategy — 2026–2028 roadmap |
| 28 | Patient Perspective — patient quotes, BMJ 2026 |
| 29 | Key References — Lancet, Harrison's, Berek & Novak's, Cecil, Tietz, etc. |
| 30 | Summary — 7 Key Messages |
Make a ppt of 25 slides of detailed review of the latest lancet article on new name change of pcod into pmos
Lancet 2026 PMOS polyendocrine metabolic ovarian syndrome Teede methodology consensus process findings
PMOS Lancet 2026 "Delphi" "nominal group" "14360" survey methodology name change implementation
Lancet PMOS methodology survey Delphi nominal group workshops timeline governance principles findings implementation companion papers
PMOS Lancet survey results preferred terms principles priorities name selection polyendocrine metabolic ovarian implementation strategy companion papers
PCOS PMOS renaming polycystic ovary polyendocrine metabolic ovarian syndrome hormonal
PMOS Lancet2026 Detailed Review 25slides
Presentation · PPTX
Slide-by-Slide Contents
| # | Slide | Key Content from Lancet Paper |
|---|---|---|
| 1 | Cover | Full citation, DOI, PMID, authors, ECE Prague announcement |
| 2 | Article at a Glance | Journal, type, DOI, lead/co-leads, 56 organisations, companion papers |
| 3 | Background — Why PCOS Had to Change | Lancet pull quote verbatim; 70% undiagnosed; 6 documented harms |
| 4 | 14-Year Journey | 2012 NIH → 2017 → 2023 → Apr 2025 → Nov 2025 → Dec 2025 → Jan 2026 → Feb 2026 → May 12 2026 timeline |
| 5 | Governance Framework | Lead institution, co-leads, AE-PCOS Society, Verity UK, 56 orgs detail |
| 6 | Study Methods Overview | 6-phase methodology: literature review → Survey A → Delphi → NGT workshops → marketing → Survey B |
| 7 | Survey Scale & Data | 22,068+ total; 14,360 new; 10,411 patients; 3,949 HCPs — with infographic stats |
| 8 | The 5 Guiding Principles | Scientific accuracy, clarity, stigma avoidance, cultural fit, implementation feasibility |
| 9 | Term Selection Process | 3 key decisions: keep acronym?, which terms?, 'syndrome' vs other? |
| 10 | Anatomy of PMOS | P·M·O·S deconstructed — each letter's clinical meaning |
| 11 | Survey A Key Findings | 82% overall / 86% patients / 70% HCPs — with % stat cards |
| 12 | Delphi & NGT Workshop Details | Workshop A (Nov 2025) & B (Feb 2026) — exact terms tested, outcomes |
| 13 | Survey B & Final Selection | PMOS vs. 4 rejected alternatives — with rationale for each rejection |
| 14 | Clinical Definition of PMOS | What it is, prevalence, scope — 'not a new condition' framing |
| 15 | Multisystem Pathophysiology | 5 axes: neuroendocrine, androgen, insulin resistance, ovarian, metabolic |
| 16 | PCOM Ultrasound Image | 4-panel Doppler + criteria table (follicle count, volume, AMH, pattern) |
| 17 | Diagnostic Criteria — Unchanged | Rotterdam 2023 under PMOS; 3 pillars; exclusion criteria |
| 18 | Burden of the Old Name | Diagnostic, clinical care, and research/policy harms — 3-column evidence |
| 19 | Implementation Strategy | 4-phase roadmap: 2026 → 2026–27 → 2027–28 → ICD 2028 |
| 20 | What Changes vs. What Doesn't | Side-by-side 8-point comparison |
| 21 | Companion Papers | 7 companion publications — BMJ, adolescents, maternal, clinical, policy, research |
| 22 | Clinical Impact for Patients | Before/after: diagnosis, consultation, metabolic care, mental health, fertility, stigma |
| 23 | Strengths of the Paper | 10 methodological and scientific strengths |
| 24 | Limitations & Future Directions | Acknowledged limitations + 2028 directions from the paper itself |
| 25 | Key Conclusions | 7 take-home messages from the Lancet paper |